PyroGenesis Canada Inc.
PYRGFOTCCIK 1743344HealthcareFiscal year ends Dec 31
Revenue is not reported in this company’s XBRL financial statements.
Latest quarter: not reported
Last eight quarters
Full statements| Line item | Unit | Shape over the periods |
|---|---|---|
| Revenue | $ | |
| Gross margin | % | |
| Operating margin | % | |
| Net margin | % | |
| Diluted EPS | $ per share | |
| Free cash flow | $ |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY2019-12-31 | FY20202020-12-31 | FY20212021-12-31 | FY20222022-12-31 | Shape over the periods |
|---|---|---|---|---|---|---|
| Revenue | $m | 4.8Revenue, period not labelled, twelve months to 2019-12-31CAD 4.8m. XBRL concept ifrs-full:Revenue. 40-F/A filed 2021-04-13, accession 0001104659-21-049824.Report this figure | 17.8Revenue, FY2020, twelve months to 2020-12-31CAD 17.8m. XBRL concept ifrs-full:Revenue. 40-F filed 2022-04-01, accession 0001410578-22-000806.Report this figure | 31.1Revenue, FY2021, twelve months to 2021-12-31CAD 31.1m. XBRL concept ifrs-full:Revenue. 40-F filed 2023-03-31, accession 0001562762-23-000149.Report this figure | 19.0Revenue, FY2022, twelve months to 2022-12-31CAD 19.0m. XBRL concept ifrs-full:Revenue. 40-F filed 2023-03-31, accession 0001562762-23-000149.Report this figure | |
| Gross margin | % | 27.0%Gross margin, period not labelled, twelve months to 2019-12-31. gross profit / revenueGross profit: CAD 1.3m. XBRL concept ifrs-full:GrossProfit. 40-F/A filed 2021-04-13, accession 0001104659-21-049824.Revenue: CAD 4.8m. XBRL concept ifrs-full:Revenue. 40-F/A filed 2021-04-13, accession 0001104659-21-049824.Report this figure | 58.0%Gross margin, FY2020, twelve months to 2020-12-31. gross profit / revenueGross profit: CAD 10.3m. XBRL concept ifrs-full:GrossProfit. 40-F filed 2022-04-01, accession 0001410578-22-000806.Revenue: CAD 17.8m. XBRL concept ifrs-full:Revenue. 40-F filed 2022-04-01, accession 0001410578-22-000806.Report this figure | 40.0%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: CAD 12.4m. XBRL concept ifrs-full:GrossProfit. 40-F filed 2023-03-31, accession 0001562762-23-000149.Revenue: CAD 31.1m. XBRL concept ifrs-full:Revenue. 40-F filed 2023-03-31, accession 0001562762-23-000149.Report this figure | 42.8%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: CAD 8.1m. XBRL concept ifrs-full:GrossProfit. 40-F filed 2023-03-31, accession 0001562762-23-000149.Revenue: CAD 19.0m. XBRL concept ifrs-full:Revenue. 40-F filed 2023-03-31, accession 0001562762-23-000149.Report this figure | |
| Operating margin | % | (168.5%)Operating margin, period not labelled, twelve months to 2019-12-31. operating income / revenueOperating income: −CAD 8.1m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 40-F/A filed 2021-04-13, accession 0001104659-21-049824.Revenue: CAD 4.8m. XBRL concept ifrs-full:Revenue. 40-F/A filed 2021-04-13, accession 0001104659-21-049824.Report this figure | (7.3%)Operating margin, FY2020, twelve months to 2020-12-31. operating income / revenueOperating income: −CAD 1.3m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 40-F filed 2022-04-01, accession 0001410578-22-000806.Revenue: CAD 17.8m. XBRL concept ifrs-full:Revenue. 40-F filed 2022-04-01, accession 0001410578-22-000806.Report this figure | (55.8%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −CAD 17.3m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 40-F filed 2023-03-31, accession 0001562762-23-000149.Revenue: CAD 31.1m. XBRL concept ifrs-full:Revenue. 40-F filed 2023-03-31, accession 0001562762-23-000149.Report this figure | (122.0%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −CAD 23.2m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 40-F filed 2023-03-31, accession 0001562762-23-000149.Revenue: CAD 19.0m. XBRL concept ifrs-full:Revenue. 40-F filed 2023-03-31, accession 0001562762-23-000149.Report this figure | |
| Net margin | % | (190.5%)Net margin, period not labelled, twelve months to 2019-12-31. net income / revenueNet income: −CAD 9.2m. XBRL concept ifrs-full:ProfitLoss. 40-F/A filed 2021-04-13, accession 0001104659-21-049824.Revenue: CAD 4.8m. XBRL concept ifrs-full:Revenue. 40-F/A filed 2021-04-13, accession 0001104659-21-049824.Report this figure | 235.0%Net margin, FY2020, twelve months to 2020-12-31. net income / revenueNet income: CAD 41.8m. XBRL concept ifrs-full:ProfitLoss. 40-F filed 2022-04-01, accession 0001410578-22-000806.Revenue: CAD 17.8m. XBRL concept ifrs-full:Revenue. 40-F filed 2022-04-01, accession 0001410578-22-000806.Report this figure | (123.7%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −CAD 38.4m. XBRL concept ifrs-full:ProfitLoss. 40-F filed 2023-03-31, accession 0001562762-23-000149.Revenue: CAD 31.1m. XBRL concept ifrs-full:Revenue. 40-F filed 2023-03-31, accession 0001562762-23-000149.Report this figure | (169.2%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −CAD 32.2m. XBRL concept ifrs-full:ProfitLoss. 40-F filed 2023-03-31, accession 0001562762-23-000149.Revenue: CAD 19.0m. XBRL concept ifrs-full:Revenue. 40-F filed 2023-03-31, accession 0001562762-23-000149.Report this figure | |
| Diluted EPS | $ per share | (0.07)Diluted EPS, period not labelled, twelve months to 2019-12-31−CAD 0.07 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 40-F/A filed 2021-04-13, accession 0001104659-21-049824.Report this figure | 0.27Diluted EPS, FY2020, twelve months to 2020-12-31CAD 0.27 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 40-F filed 2022-04-01, accession 0001410578-22-000806.Report this figure | (0.23)Diluted EPS, FY2021, twelve months to 2021-12-31−CAD 0.23 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 40-F filed 2023-03-31, accession 0001562762-23-000149.Report this figure | (0.19)Diluted EPS, FY2022, twelve months to 2022-12-31−CAD 0.19 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 40-F filed 2023-03-31, accession 0001562762-23-000149.Report this figure | |
| Free cash flow | $m | (4.1)Free cash flow, period not labelled, twelve months to 2019-12-31. operating cash flow − capital expenditureOperating cash flow: −CAD 3.3m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 40-F/A filed 2021-04-13, accession 0001104659-21-049824.Capital expenditure: CAD 823.0k. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 40-F/A filed 2021-04-13, accession 0001104659-21-049824.Report this figure | (1.5)Free cash flow, FY2020, twelve months to 2020-12-31. operating cash flow − capital expenditureOperating cash flow: −CAD 815.0k. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 40-F filed 2022-04-01, accession 0001410578-22-000806.Capital expenditure: CAD 702.1k. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 40-F filed 2022-04-01, accession 0001410578-22-000806.Report this figure | (19.6)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −CAD 18.1m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 40-F filed 2023-03-31, accession 0001562762-23-000149.Capital expenditure: CAD 1.5m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 40-F filed 2023-03-31, accession 0001562762-23-000149.Report this figure | (11.5)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −CAD 11.1m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 40-F filed 2023-03-31, accession 0001562762-23-000149.Capital expenditure: CAD 396.1k. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 40-F filed 2023-03-31, accession 0001562762-23-000149.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| HUNTINGTON NATIONAL BANK | 2026-06-30 | $14.5k | 100,000 | Unchanged |
Recent filings
All 163 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2023-11-1405:53 ET | 6-K | Report of a foreign private issuerPeriod 2023-09-30 | 0001171843-23-007086 |
| 2023-11-0912:20 ET | 6-K | Report of a foreign private issuerPeriod 2023-11-09 | 0001171843-23-006965 |
| 2023-11-0805:21 ET | 6-K | Report of a foreign private issuerPeriod 2023-11-07 | 0001171843-23-006852 |
| 2023-10-3005:30 ET | 6-K | Report of a foreign private issuerPeriod 2023-10-27 | 0001171843-23-006523 |
| 2023-10-2506:02 ET | 6-K | Report of a foreign private issuerPeriod 2023-10-24 | 0001171843-23-006379 |
| 2023-10-1103:00 ET | 6-K | Report of a foreign private issuerPeriod 2023-10-11 | 0001171843-23-006202 |
| 2023-10-0305:32 ET | 6-K | Report of a foreign private issuerPeriod 2023-10-03 | 0001171843-23-006003 |
| 2023-09-1913:22 ET | 6-K | Report of a foreign private issuerPeriod 2023-09-19 | 0001171843-23-005789 |
| 2023-09-1211:44 ET | 6-K | Report of a foreign private issuerPeriod 2023-09-12 | 0001171843-23-005677 |
| 2023-09-0507:15 ET | 6-K | Report of a foreign private issuerPeriod 2023-08-31 | 0001171843-23-005555 |
Latest annual report
Form 40-F for the fiscal year ended Dec 31, 2022Filed Mar 31, 2023. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 1743344
- Tickers
- PYRGF
- Exchange
- OTC
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- Dec 31
- Incorporated in
- A8
- Filer category
- <br>Emerging growth company
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. Listed shows no prices and gives no investment advice.